Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-26 @ 3:17 PM
NCT ID: NCT07351669
Eligibility Criteria: Inclusion Criteria01: 1. Voluntary participation and ability to sign informed consent (post-TACE); 2. Age between 18 and 75 years; 3. Diagnosed as HCC based on pathology or clinical criteria, with a BCLC stage of A or B; 4. Patients undergo contrast-enhanced spectral CT 4-8 weeks after treatment and are assessed as complete response on conventional CT images; 5. Patients are scheduled to undergo surgical resection within one month, or DSA hepatic arteriography or contrast-enhanced MRI within one week. If none of these were planned, the patients were scheduled for imaging follow-up (CT or MRI) every 3 months (±15 days) for at least one year. Inclusion Criteria02: 1. Voluntary participation and ability to sign informed consent (post-TACE, cTACE or DEB-TACE); 2. Age between 18 and 75 years; 3. Diagnosed as HCC based on pathology or clinical criteria, with a BCLC stage of A or B; 4. Patients plan to undergo liver tumor resection following TACE downstaging therapy; 5. Contrast-enhanced spectral CT was performed within 7 days before liver resection, after completion of TACE down-staging treatment. Exclusion Criteria: 1. Contraindications to contrast-enhanced CT or contrast-enhanced MRI; 2. Presence of extrahepatic malignancies; 3. History of radiotherapy; 4. Poor image quality or incomplete clinical/imaging data; Withdrawal from the study midway.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT07351669
Study Brief:
Protocol Section: NCT07351669